Fig. 1 · Structure

Documents & Downloads

Silodosin

Cat. No. A10843 CAS 160970-54-7

α1-adrenoceptor antagonist

Silodosin(Rapaflo) is an α1-adrenoceptor antagonist with high uroselectivity. It causes practically no orthostatic hypotension (in contrast to other α1 blockers).

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
α1-adrenergic receptor

Cellular Effect

Cell Line Activity Value Description Reference
HEK293 IC50 1.8 nM Antagonist activity at human full-length N-terminal SNAP-tagged alpha1A adrenoceptor expressed in HEK293 cells assessed as inhibition of agonist-induced calcium mobilization preincubated for 10 mins followed by agonist addition by fluo-4 AM dye-based assa [PMID: 27709945]
HEK293 IC50 1.9 nM Antagonist activity at human alpha-1A adrenergic receptor transfected in HEK293 cells assessed as reduction in agonist-induced calcium mobilization after 10 mins [PMID: 27031406]
HEK293 IC50 116 nM Antagonist activity at human full-length N-terminal SNAP-tagged alpha1B adrenoceptor expressed in HEK293 cells assessed as inhibition of agonist-induced calcium mobilization preincubated for 10 mins followed by agonist addition by fluo-4 AM dye-based assa [PMID: 27709945]
HEK293 IC50 27.3 nM Antagonist activity at alpha-1D adrenergic receptor (unknown origin) transfected in HEK293 cells assessed as reduction in agonist-induced calcium mobilization after 10 mins [PMID: 27031406]
HEK293 IC50 541.4 nM Antagonist activity at human alpha-1B adrenergic receptor transfected in HEK293 cells assessed as reduction in agonist-induced calcium mobilization after 10 mins [PMID: 27031406]
HEK293 IC50 6.3 nM Antagonist activity at human full-length N-terminal SNAP-tagged alpha1D adrenoceptor expressed in HEK293 cells assessed as inhibition of agonist-induced calcium mobilization preincubated for 10 mins followed by agonist addition by fluo-4 AM dye-based assa [PMID: 27709945]

In Vitro Studies

Silodosin was evaluated for cell proliferation in MCF-7 and MDA-MB-231 cells treated in serum-free medium for 48 hours, with DMSO as the vehicle control. The reported IC50 in MCF-7 cells was 26 µmol/L; the reported cell proliferation readout value in MDA-MB-231 cells was 35 µmol/L. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Silodosin and MCF-7 Cell Proliferation

Cell-based study · MCF-7 [1]

MCF-7 cells were treated with Silodosin in serum-free medium for 48 hours, with DMSO as the vehicle control. The reported cell proliferation IC50 was 26 µmol/L.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell proliferationIC50 26 µmol/L[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 to 50 µM
Exposure duration
48 hours
Method
treated in a serum-free medium
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: Silodosin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > SIL reduces breast cancer cell growth (S9); Materials and methods > Cell culture and treatments (S83, S84); Materials and methods > Cell proliferation assay (S89, S90); Fig. 1 legend (S172)

Cell proliferation: Cell proliferation; comparator: vehicle (DMSO, control, Ctrl) — Results > SIL reduces breast cancer cell growth (S9); Materials and methods > Cell proliferation assay (S90)

Silodosin and MDA-MB-231 Cell Proliferation

Cell-based study · MDA-MB-231 [1]

MDA-MB-231 cells were treated with Silodosin in serum-free medium for 48 hours, with DMSO as the vehicle control. The reported cell proliferation readout value was 35 µmol/L.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell proliferationIC50 35 µmol/L[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 to 50 µM
Exposure duration
48 hours
Method
treated in a serum-free medium
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: Silodosin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > SIL reduces breast cancer cell growth (S9); Materials and methods > Cell culture and treatments (S83, S84); Materials and methods > Cell proliferation assay (S89, S90); Fig. 1 legend (S172)

Cell proliferation: Cell proliferation; comparator: vehicle (DMSO, control, Ctrl) — Results > SIL reduces breast cancer cell growth (S9); Materials and methods > Cell proliferation assay (S90)

In Vivo Studies

In male Wistar rats, oral Silodosin plus phenylephrine inhibited parotid AQP5 trafficking to the APM and LPM compared with saline plus phenylephrine. In male SD rats with BPH, oral Silodosin significantly reduced urinary frequency and increased mean voided volume in a dose-dependent manner compared with vehicle control, with a minimal effective dose of 1 mg/kg. [2,3]

Silodosin Plus Phenylephrine and Parotid AQP5 Trafficking

Animal study · Eight-week-old male Wistar rats [2]

Male Wistar rats received oral Silodosin at 1 mg/kg once daily for 1 week. Silodosin plus phenylephrine inhibited AQP5 trafficking to the APM and LPM in rat parotid tissue, compared with saline plus phenylephrine.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
phenylephrine-induced translocation of AQP5 to the APM and LPMReported result silodosin plus phenylephrine (Figure 4; D-1) treatment of rat parotid tissue resulted in inhibition of AQP5 trafficking to the APM and LPM[2]

Conditions shared by the study groups

Route
oral administration
Treatment course
once daily for 1 week
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Silodosin 1 mg/kgsaline plus phenylephrinesilodosin plus phenylephrine (Figure 4; D-1) treatment of rat parotid tissue resulted in inhibition of AQP5 trafficking to the APM and LPM[2]
Silodosin 1 mg/kg
Model: Eight-week-old male Wistar rats
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Silodosin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.5. Prevention of Phenylephrine-Induced Trafficking of AQP5 by α1A-AR Antagonist (S30, S33, S37); 4. Materials and Methods > 4.2. Animals (S84); 4. Materials and Methods > 4.3. Immunohistochemistry (S89, S92, S93, S94); Figure 4 legend (S146, S147)

phenylephrine-induced translocation of AQP5 to the APM and LPM: phenylephrine-induced translocation of AQP5 to the APM and LPM; comparator: saline plus phenylephrine — 2. Results > 2.5. Prevention of Phenylephrine-Induced Trafficking of AQP5 by α1A-AR Antagonist (S30, S33)

Silodosin 1 mg/kg · 2. Results > 2.5. Prevention of Phenylephrine-Induced Trafficking of AQP5 by α1A-AR Antagonist (S33); 4. Materials and Methods > 4.3. Immunohistochemistry (S89); Figure 4 legend (S146)

Silodosin and Voiding Outcomes in BPH Rats

Animal study · Male SD rats (200–250 g) [3]

Male SD rats with BPH received oral Silodosin. Compared with vehicle control, Silodosin significantly reduced urinary frequency and increased mean voided volume in a dose-dependent manner, with a minimal effective dose of 1 mg/kg.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Micturition frequencyReported result silodosin significantly reduced the urinary frequency and increased the mean voided volume in BPH rats in a dose-dependent manner, with the minimal effective dose of 1 mg/kg[3]

Conditions shared by the study groups

Route
oral administration
Treatment course
Two days after a lower-dose testing, animals were used for the next higher-dose testing.
Vehicle
0.5% carboxymethyl cellulose sodium
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Silodosin 0.3, 1, 3, and 10 mg/kgvehicle controlsilodosin significantly reduced the urinary frequency and increased the mean voided volume in BPH rats in a dose-dependent manner, with the minimal effective dose of 1 mg/kg[3]
Silodosin 0.3, 1, 3, and 10 mg/kg
Model: Male SD rats (200–250 g)
Methods and source locations

Compound reported in the paper: Silodosin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Animals (S5); Materials and methods > Micturition recording (S25, S26, S27, S28, S29); Results > Testosterone propionate induces BPH in rats (S39, S40); Results > Silodosin improves micturition parameters in testosterone-induced BPH rats (S48); Fig 2 legend (S72)

Micturition frequency: Micturition frequency; comparator: vehicle control — Results > Silodosin improves micturition parameters in testosterone-induced BPH rats (S48); Fig 2 legend (S72)

Silodosin 0.3, 1, 3, and 10 mg/kg · Materials and methods > Micturition recording (S26, S27, S28); Results > Silodosin improves micturition parameters in testosterone-induced BPH rats (S48)

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 160970-54-7
Applications α1-adrenoceptor antagonist
Formula C25H32F3N3O4
Molecular Weight 495.5
Synonyms KAD 3213; KMD 3213; Rapaflo
SMILES
C[C@H](Cc1cc2c(c(C(N)=O)c1)N(CCCO)CC2)NCCOc1ccccc1OCC(F)(F)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 97 mg/mL (195.74 mM)
Water Insoluble
Ethanol 97 mg/mL (195.74 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Pellegrino M, Occhiuzzi MA, Marra M, et al. Molecular insights into Silodosin's anti-cancer effects: a promising repurposing strategy for breast cancer. Cell Death Discov (2026). PMID: 41781389 DOI: 10.1038/s41420-026-02973-8 Source material
  2. [2] Bragiel AM, Wang D, Pieczonka TD, et al. Mechanisms Underlying Activation of α₁-Adrenergic Receptor-Induced Trafficking of AQP5 in Rat Parotid Acinar Cells under Isotonic or Hypotonic Conditions. Int J Mol Sci (2016). PMID: 27367668 DOI: 10.3390/ijms17071022 Source material
  3. [3] Li J, Tian Y, Guo S, et al. Testosterone-induced benign prostatic hyperplasia rat and dog as facile models to assess drugs targeting lower urinary tract symptoms. PLoS One (2018). PMID: 29351556 DOI: 10.1371/journal.pone.0191469 Source material

Added to your cart

View Cart Checkout
Loading...